🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
1,179

Quick answer

Takeda has 1,179 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Parathyroid hormone

    Takeda

    Disruption or Dehiscence of Closure of Sternum or Sternotomy

    phase 3 small molecule completed

    1 trial

  2. Pioglitazone

    Takeda

    HIV-Associated Lipodystrophy Syndrome

    phase 3 small molecule terminated

    1 trial

  3. Pioglitazone

    Takeda

    Impaired Glucose Tolerance

    phase 3 small molecule completed

    1 trial

  4. Pioglitazone

    Takeda

    Mild Cognitive Impairment Due to Alzheimer's Disease

    phase 3 small molecule terminated

    2 trials

  5. Pioglitazone and Azilsartan

    Takeda

    Type 2 Diabetes

    phase 3 small molecule terminated

    1 trial

  6. Pioglitazone and Glimepiride

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  7. Pioglitazone-Azilsartan

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule terminated

    1 trial

  8. Placebo

    Takeda

    Generalized Anxiety Disorder

    phase 3 small molecule completed

    1 trial

  9. Placebo

    Takeda

    Diabetes

    phase 3 small molecule terminated

    1 trial

  10. Placebo

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    2 trials

  11. Placebo

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  12. Placebo

    Takeda

    Male Subjects With Chronic Constipation

    phase 3 small molecule completed

    1 trial

  13. Placebo

    Takeda

    Hypoparathyroidism

    phase 3 small molecule completed

    1 trial

  14. Placebo

    Takeda

    Healthy Volunteers

    phase 3 small molecule completed

    2 trials

  15. Placebo

    Takeda

    Lennox Gastaut Syndrome (LGS)

    phase 3 small molecule completed

    1 trial

  16. Placebo

    Takeda

    Hypertension

    phase 3 small molecule terminated

    1 trial

  17. Placebo

    Takeda

    Short Bowel Syndrome

    phase 3 small molecule completed

    1 trial

  18. Placebo

    Takeda

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  19. Placebo

    Takeda

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  20. Placebo

    Takeda

    Chronic Idiopathic Constipation

    phase 3 small molecule completed

    1 trial

  21. Placebo

    Takeda

    Non-erosive Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    1 trial

  22. Ponatinib

    Takeda

    Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

    phase 3 small molecule active

    1 trial

  23. Ponatinib 30 mg QD

    Takeda

    Chronic Phase Chronic Myeloid Leukemia

    phase 3 small molecule terminated

    1 trial

  24. Protein C Concentrate (Human) Vapor Heated

    Takeda

    Protein C Deficiency

    phase 3 small molecule completed

    1 trial

  25. Prucalopride

    Takeda

    Constipation

    phase 3 small molecule terminated

    1 trial

  26. R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm

    Takeda

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  27. RIFAXIMIN , VANCOMYCIN , Entyvio 300 mg powder for concentrate for solution for infusion, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CIPROFLOXACIN , METRONIDAZOLE

    Takeda

    Active Chronic Pouchitis

    phase 3 small molecule active

    1 trial

  28. Ramelteon

    Takeda

    Transient Insomnia

    phase 3 small molecule completed

    1 trial

  29. Ramelteon

    Takeda

    Sleep Initiation and Maintenance Disorders

    phase 3 small molecule completed

    2 trials

  30. Ramelteon

    Takeda

    Balance

    phase 3 small molecule completed

    1 trial

  31. Ramelteon SL

    Takeda

    Acute Depressive Episode

    phase 3 small molecule terminated

    1 trial

  32. Ramelteon SL

    Takeda

    Bipolar Disorder

    phase 3 small molecule terminated

    1 trial

  33. Ramelteon SL (Dose 1)

    Takeda

    Bipolar Disorder

    phase 3 small molecule terminated

    1 trial

  34. Ramelteon and Placebo (9 possible combinations total)

    Takeda

    Chronic Insomnia

    phase 3 small molecule completed

    1 trial

  35. Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial

  36. Recombinant Factor VIIa BI (rFVIIa BI)

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial

  37. Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)

    Takeda

    Hemophilia A

    phase 3 mab terminated

    1 trial

  38. Recombinant factor IX

    Takeda

    Hemophilia B

    phase 3 mab completed

    1 trial

  39. Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  40. Recombinant von Willebrand factor (rVWF)

    Takeda

    Von Willebrand Disease

    phase 3 mab completed

    2 trials

  41. Relugolix

    Takeda

    Uterine Fibroids

    phase 3 small molecule completed

    2 trials

  42. Resatorvid

    Takeda

    Sepsis

    phase 3 small molecule completed

    2 trials

  43. Rituximab 375 mg/m^2

    Takeda

    Mantle Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  44. SALINE, Fazirsiran

    Takeda

    Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

    phase 3 small molecule active

    1 trial

  45. SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  46. SHP465

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    4 trials

  47. SHP465 12.5mg capsules (one capsule daily)

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  48. SHP615

    Takeda

    Nervous System Diseases

    phase 3 small molecule completed

    2 trials

Frequently asked questions

How many pipeline programs does Takeda have?

1,179 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.